GlassScriptPhysician profile
Todd Nicholas Tom
NPI 1154327559
$9,010.53
in general payments reported to CMS, 2019-2025
27 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.79 · 2020: $193 · 2021: $60.61 · 2022: $4,962 · 2023: $3,002 · 2024: $616 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,765 · Education: $1,000 · Food and Beverage: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,764.91 |
| Education | $1,000.00 |
| Food and Beverage | $989.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,401.44 | 2022-2023 | Da Vinci Surgical System, Davinci Xi |
| Tela Bio, INC. | $1,150.46 | 2022-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Solventum Corporation | $253.73 | 2024-2025 | Prevena, Activ.A.C., V.A.C. Granufoam |
| Aroa Biosurgery Incorporated | $248.00 | 2024-2025 | |
| Endomagnetics LTD | $132.89 | 2020 | |
| Integra Lifesciences Corporation | $87.22 | 2022-2024 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Daiichi Sankyo INC. | $85.43 | 2020-2021 | |
| Organogenesis INC. | $81.81 | 2023-2024 | Puraply Am, Puraply |
| Kci USA, INC. | $73.06 | 2022 | |
| Ethicon US, LLC | $54.78 | 2022-2025 | Vistaseal, Dermabond |
| Polymedics Innovations INC. | $41.14 | 2023 | |
| C. R. Bard, INC. & Subsidiaries | $39.79 | 2019 | |
| Polynovo North America LLC | $39.09 | 2023 | |
| Smith+Nephew, INC. | $36.22 | 2023 | Renasys Go V2 Home |
| Baxter Healthcare | $33.67 | 2022-2024 | Perclot |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimvie INC. | $32.10 | 2022-2023 | |
| Convatec INC. | $27.15 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $24.39 | 2024 | Exparel |
| Paratek Pharmaceuticals, INC. | $23.23 | 2025 | Nuzyra |
| Hologic Sales and Service, LLC | $20.76 | 2025 | Magseed |
| Myriad Genetic Laboratories, INC. | $20.50 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $19.75 | 2022 | |
| Next Science LLC | $19.74 | 2022 | |
| Dilon Technologies, INC. | $18.99 | 2024 | Hemoblast Bellows |
| Olympus America INC. | $15.85 | 2022 | |
| Lilly USA, LLC | $14.81 | 2020 | |
| Heron Therapeutics, INC. | $14.53 | 2023 | Zynrelef |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Tom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.